27357626|t|Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma
27357626|a|Adoptive T-cell transfer is a promising treatment approach for metastatic cancer, but efficacy in solid tumors has only been achieved with toxic pre- and postconditioning regimens. Thus, adoptive T-cell therapies would benefit from complementary modalities that enable their full potential without excessive toxicity. We aimed to improve the efficacy and safety of adoptive T-cell transfer by using adenoviral vectors for direct delivery of immunomodulatory murine cytokines into B16.OVA melanoma tumors with concomitant T-cell receptor transgenic OT-I T-cell transfer. Armed adenoviruses expressed high local and low systemic levels of cytokine when injected into B16.OVA tumors, suggesting safety of virus-mediated cytokine delivery. Antitumor efficacy was significantly enhanced with adenoviruses coding for murine interleukin-2 (mIL-2) and tumor necrosis factor-α (mTNFα) when compared with T-cell transfer alone or viruses alone. Further improvement in efficacy was achieved with a triple combination of mIL-2, mTNFα, and OT-I T-cells. Mechanistic studies suggest that mIL-2 has an important role in activating T-cells at the tumor, while mTNFα induces chemokine expression. Furthermore, adenovirus treatments enhanced tumor - infiltration of OT-I T-cells as demonstrated by SPECT/CT imaging of (111)In-labeled cells. Our results suggest the utility of cytokine-coding adenoviruses for improving the efficacy of adoptive T-cell therapies.
27357626	0	10	Adenoviral	T005	C0001483
27357626	11	19	Delivery	T061	C0011209
27357626	23	46	Tumor Necrosis Factor-α	T116,T129	C1456820
27357626	51	64	Interleukin-2	T116,T129	C0021756
27357626	84	105	Adoptive Cell Therapy	T061	C0079613
27357626	109	126	Immunosuppressive	T121,T129	C0021081
27357626	127	135	Melanoma	T191	C0025202
27357626	136	160	Adoptive T-cell transfer	T061	C0376517
27357626	176	194	treatment approach	UnknownType	C0679624
27357626	199	216	metastatic cancer	T191	C0027627
27357626	222	230	efficacy	T080	C1280519
27357626	234	246	solid tumors	T191	C0280100
27357626	275	280	toxic	T080	C1407029
27357626	323	348	adoptive T-cell therapies	T061	C0079613
27357626	355	362	benefit	T081	C0814225
27357626	382	392	modalities	T078	C0695347
27357626	411	415	full	T080	C0443225
27357626	416	425	potential	T080	C3245505
27357626	434	443	excessive	T080	C0442802
27357626	444	452	toxicity	T080	C0040539
27357626	457	462	aimed	T078	C1947946
27357626	466	473	improve	T080	C1272745
27357626	478	486	efficacy	T080	C1280519
27357626	491	497	safety	T080	C0205556
27357626	501	525	adoptive T-cell transfer	T061	C0376517
27357626	535	553	adenoviral vectors	T114	C1510800
27357626	565	573	delivery	T169	C1705822
27357626	577	593	immunomodulatory	T061	C1963758
27357626	594	600	murine	T015	C0026809
27357626	601	610	cytokines	T116,T129	C0079189
27357626	616	623	B16.OVA	T025	C0029974
27357626	624	639	melanoma tumors	T050,T191	C0004565
27357626	633	639	tumors	T191	C0027651
27357626	645	656	concomitant	T079	C0521115
27357626	657	672	T-cell receptor	T116,T129,T192	C0034790
27357626	673	688	transgenic OT-I	T015	C0025936
27357626	673	704	transgenic OT-I T-cell transfer	T061	C0376517
27357626	712	724	adenoviruses	T005	C0001483
27357626	773	781	cytokine	T116,T129	C0079189
27357626	787	795	injected	T169	C0449894
27357626	801	808	B16.OVA	T025	C0029974
27357626	809	815	tumors	T191	C0027651
27357626	828	834	safety	T080	C0205556
27357626	838	852	virus-mediated	T005	C0042776
27357626	838	870	virus-mediated cytokine delivery	T061	C0011209
27357626	853	861	cytokine	T116,T129	C0079189
27357626	872	881	Antitumor	T080	C2986475
27357626	882	890	efficacy	T080	C1280519
27357626	909	917	enhanced	T052	C2349975
27357626	923	935	adenoviruses	T005	C0001483
27357626	947	953	murine	T015	C0026809
27357626	954	967	interleukin-2	T116,T129	C0021756
27357626	969	974	mIL-2	T116,T129	C0021756
27357626	980	1003	tumor necrosis factor-α	T116,T129	C1456820
27357626	1005	1010	mTNFα	T116,T129	C1456820
27357626	1031	1046	T-cell transfer	T061	C0376517
27357626	1056	1063	viruses	T005	C0042776
27357626	1079	1090	improvement	T077	C2986411
27357626	1094	1102	efficacy	T080	C1280519
27357626	1123	1129	triple	T081	C0205174
27357626	1130	1141	combination	T080	C0205195
27357626	1145	1150	mIL-2	T116,T129	C0021756
27357626	1152	1157	mTNFα	T116,T129	C1456820
27357626	1163	1175	OT-I T-cells	T025	C0039194
27357626	1177	1196	Mechanistic studies	T169	C0441712
27357626	1210	1215	mIL-2	T116,T129	C0021756
27357626	1223	1232	important	T080	C3898777
27357626	1233	1237	role	T077	C1705810
27357626	1241	1251	activating	T052	C1879547
27357626	1252	1259	T-cells	T025	C0039194
27357626	1267	1272	tumor	T191	C0027651
27357626	1280	1285	mTNFα	T116,T129	C0041368
27357626	1294	1303	chemokine	T116,T129	C0282554
27357626	1304	1314	expression	T045	C1171362
27357626	1329	1339	adenovirus	T005	C0001483
27357626	1340	1350	treatments	T061	C0087111
27357626	1351	1359	enhanced	T052	C2349975
27357626	1360	1365	tumor	T191	C0027651
27357626	1384	1396	OT-I T-cells	T025	C0039194
27357626	1400	1412	demonstrated	T052	C3687625
27357626	1416	1432	SPECT/CT imaging	T060	C3472245
27357626	1436	1457	(111)In-labeled cells	T025	C0007634
27357626	1463	1470	results	T169	C1274040
27357626	1471	1478	suggest	T078	C1705535
27357626	1494	1509	cytokine-coding	T116,T129	C0079189
27357626	1510	1522	adenoviruses	T005	C0001483
27357626	1527	1536	improving	T080	C1272745
27357626	1541	1549	efficacy	T080	C1280519
27357626	1553	1578	adoptive T-cell therapies	T061	C0079613